Pediatric obesity is a highly prevalent chronic disease, which has traditionally been treated
with lifestyle therapy alone. Yet for many youth, lifestyle intervention as a monotherapy is …

Abstract Background A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-
like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Background Obesity is a chronic disease with limited treatment options in pediatric patients.
Liraglutide may be useful for weight management in adolescents with obesity. Methods In …

Objectives To determine the weight, body mass index (BMI), cardiometabolic, and
gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with …

Childhood obesity has been increasing steadily in recent decades, and severe childhood
obesity has emerged as a major public health problem both nationally and internationally. A …

Pharmacological options for management of obesity and type 2 diabetes mellitus (T2DM) in
children are limited. We aimed to synthesize published randomized controlled trial (RCT) …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Obesity derives from impaired central control of body weight, implying interaction between
environment and an individual genetic predisposition. Genetic obesities, including …

Abstract This Position Statement updates the different components of the therapy of obesity
(lifestyle intervention, drugs, and surgery) in children and adolescents, previously reported …